IL1B and diabetes mellitus: In addition, the promoting effects of the miR-30e-5p inhibitor on IL-1β and IL-18 expression were dramatically reversed by ELAVL1 knockdown in the BMSC-exo-treated diabetes model cells (Figure 6(G)).